Biden's first year in office plagued by broken promises on

New Post Public Reply Private Reply Replies (2) Message Board
Rusty dbergh #75406
338
Biden's first year in office plagued by broken promises on COVID-19

Biden’s broken promises on getting the coronavirus pandemic under control have come into full view as he wraps up his first year in office and the omicron variant continues its sweep across the country.

While Biden has seen tanking approval ratings on issues like the economy and inflation, he has typically enjoyed higher numbers on his handling of COVID-19, but that, too, has dropped over the course of the past year. According to a new ABC News/Ipsos poll, 53% approve of Biden’s response to the coronavirus, down from 69% when he first took office, with a considerable drop among independents.

The drop comes as the White House tries to shift its messaging around the coronavirus to focus on hospitalizations and deaths instead of the number of cases. The seven-day rolling average of new COVID-19 cases was 193,002 new cases per day when Biden took office on Jan. 20. That number decreased in the summer but ballooned to 240,408 new cases per day on Monday, the highest average reached under the Biden Administration.

White House press secretary Jen Psaki acknowledged Friday that there’s "no question" the pandemic is negatively affecting Biden's polling.

"This is a really tough time in our country," she said. "We’re still battling COVID and a lot of people thought we’d be through it, including us."

Biden, who recently said "the single greatest currency you have is your word," made big promises regarding COVID-19 on the campaign trail that have yet to come to fruition. Despite his repeated vows to "shut down the virus," the number of deaths under his watch has surpassed those under Trump, despite the prevalence of vaccinations that did not exist under the former president.

Vice President Kamala Harris echoed Biden multiple times on her Twitter account in the weeks after the 2020 election, saying she and Biden would "get this virus under control."

Biden has also reversed his position on vaccine mandates. When he was still president-elect, he told reporters that he didn’t believe the COVID-19 vaccine should be mandatory and that he "would not demand that it be mandatory." Psaki reiterated during a July press conference that it is "not the role of the federal government" to mandate the vaccine.

Biden reneged on that promise in September amid a new wave of cases due to the delta variant, announcing a six-part plan to slow the spread, including vaccine mandates for federal workers, government contractors and private businesses with 100 or more employees.

The Biden administration has also been fiercely criticized on both sides of the aisle over footage of people waiting in long lines for hours to obtain a COVID-19 test ahead of the busy holiday travel season. Biden had promised to fix the testing issues faced by the previous administration, signing an executive order upon his inauguration appointing a COVID-19 response coordinator to handle the distribution of tests.

Biden acknowledged this week that his efforts had fallen short, and he has since promised to make 500 million coronavirus tests available free of charge, but the administration has not yet signed a contract to buy the tests and has not said when the tests will be delivered.

The president also took a dramatically different tone when he said Monday that "there is no federal solution" to the pandemic and that it was up to governors — a sentiment that was much maligned by Biden and the Democrats under the Trump administration.

Biden has also failed to follow through on his promise to hold China accountable for its handling of the virus that causes COVID-19. During his campaign, Biden said he would "not be taking China’s word for it" and would "insist" that the communist country cooperate with a U.S. investigation into its origins. Since taking office, Biden has had three speaking engagements with Chinese President Xi Jinping and has not raised the issue once.

A much-anticipated U.S. intelligence community’s review of the virus’ origins in August said it’s possible the virus leaked from the Wuhan Institute of Virology, but it failed to reach any definite conclusions. Biden issued a strongly worded statement on Aug. 27 after the review concluded, saying he "will not rest" until the world gets answers, but he has not mentioned the issue publicly since.

Meanwhile, Trump blasted Biden as "bowing down to China" and being complicit in the "coverup" in his year-end newsletter to supporters on Tuesday.

https://news.yahoo.com/biden-apos-first-offic...01195.html
Scroll down for more posts ▼

Top 10 Most Recent News Articles

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 249

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Tencent Cloud's Edge Platform Shines in New Gartner Report

Updated Category News Views 61

The Breakthrough in Edge Computing Everyone's talking about cloud this and cloud that, but Tencent Cloud is taking things a notch further with its EdgeOne platform. It's not just about storing your files in the sky; it's about having the fastest, most secure delivery possible. Gartner's latest report puts these guys right at the top in their Magic Quadrant for Edge...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 307

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Strathcona and Greenfire Set Sights on Major Merger

Updated Category News Views 138

Strathcona's Bold Move for Greenfire: A Game Changer? Just this week, Strathcona Resources Ltd. decided to make a big splash in the oil sands space by proposing to acquire Greenfire Resources Ltd. This isn’t your run-of-the-mill grab—it's a strategic tango expected to shift billions and reshape what we know about Canada’s oil sands territory. Unpicking the Deal...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 203

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Cars.com Inducement Awards: New CPO Earns Stock Boost

Updated Category News Views 76

Revving Up With Incentives: A Strategic Move by Cars.com Ever seen a stock maneuver that feels more like a chess play than a plain deal? On November 5, 2026, Cars.com (NYSE: CARS) fired up quite a strategic engine. They handed out a heap of restricted stock units—373,345 to be precise—to Mausam Bhatt, freshly minted as their Chief Product Officer. This isn't just your...

Continue Reading
AI Shopping Surge: WeFetch.ai's Bold Rebrand Move

Updated Category News Views 48

Shifting Gears: GreenCore Solutions Becomes WeFetch.ai Here's a shift you don't see every day. GreenCore Solutions has morphed into WeFetch.ai, aiming to sail the ever-growing AI shopping seas. This isn't just a new nameplate; it's a declaration of intent to dive headfirst into the market dynamics driven by artificial intelligence. It's bold and, frankly, pretty timely....

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 149

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
Mako Hiraizumi Shines with Silver at Japan Triathlon

Updated Category News Views 41

A Triathlete with Grit and Ambition Mako Hiraizumi didn't just earn a silver medal at the 32nd Japan Triathlon National Championships; she set an example of perseverance and ambition. Rising a notch from her bronze finish last year, Hiraizumi's runner-up achievement at Tokyo's Odaiba Seaside Park is no small feat. Yet, she's not resting on her laurels. This athlete from...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 482

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading

Top 5 Most Recently Viewed Articles

Abeona Therapeutics' ZEVASKYN Receives FDA Approval, a New Hope

Updated Category News Views 147

A Revolutionary Breakthrough for Epidermolysis Bullosa In an incredible achievement for the EB community, Abeona Therapeutics has received FDA approval for ZEVASKYN, which is poised to change the landscape for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). This marks a historic moment as the third FDA-approved treatment for RDEB and the first autologous,...

Continue Reading
Zero Candida Reaches Major Milestone with ZC-001 Device Development

Updated Category News Views 127

Zero Candida Marks Milestone with ZC-001 Prototype Production Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) has achieved a remarkable milestone in its quest to revolutionize women's health. The company recently announced the commencement of prototype production for its groundbreaking therapeutic device, ZC-001, designed specifically for the treatment of...

Continue Reading
Bitcoin's Future and Market Dynamics: Insights from a Veteran Trader

Updated Category News Views 86

Cautious Optimism for Bitcoin and Other Cryptocurrencies Pseudonymous veteran trader DonAlt expresses a cautious outlook on leading cryptocurrencies like Bitcoin, Ethereum, and Dogecoin. His insights on market trends reveal an intriguing perspective for investors in these digital assets. Current Market Situation DonAlt has recently shared his thoughts on the performance...

Continue Reading
Alibaba Settles for $433.5 Million in Shareholder Lawsuit

Updated Category News Views 220

Alibaba Reaches Settlement in Lawsuit Alibaba (NYSE: BABA), China’s leading e-commerce powerhouse, has recently taken a significant step in addressing legal challenges by agreeing to pay $433.5 million to settle a class-action lawsuit in the United States. This lawsuit, brought forth by investors, accused Alibaba of engaging in monopolistic practices. The company's...

Continue Reading
Class Action Alert: Telix Pharmaceuticals Lawsuit Overview

Updated Category News Views 174

Understanding the Telix Pharmaceuticals Class Action In a significant development, investors of Telix Pharmaceuticals Limited are currently facing a class action lawsuit. This initiative, spearheaded by Bronstein, Gewirtz & Grossman LLC, invites those affected by substantial losses in their investments to take action. The law firm is renowned for its dedication in...

Continue Reading